Ariad Pharmaceuticals Inc fka ARIA

[DewDiligence]

The biggest risks to a long are the instability of the market, the expected dilution, and the conjectured untrustworthiness of the CEO.

To the latter point, the instances of pumping by ARIA executives continue to expand. We saw in #msg-68259377 how management hyped the fact that the Ponatanib NDA was “already being written.” Now, we have the tautological tout in #msg-69013537 that “no patient failed” in the PACE trial if they were a complete responder.

While the kind of behavior cited above is far from probative, in my experience it does have a mild negative correlation with ultimate success.